Keypoints Overview
Phare Pharmaceuticals is pioneering Europe’s first chemical-free “Clean Cannabis” with cutting-edge tech.
Through the use of AI, automation and a century of industry best practices Phare Pharmaceuticals will develop one of the most technologically advanced cannabis facilities in Europe.
Cannabis as Medicine: Phare Pharmaceuticals facilities are specially designed to produce the first “Clean Cannabis” products in the EU utilizing solventless technologies. Solventless extraction eliminates the use of chemicals or hydrocarbons during the extraction process,Creating a clean pure cannabis extract.
Innovation
Overseeing the most advanced cannabis greenhouses in Europe, focused on automation and A.I. advanced computing. Phare is the most efficient quality cannabis producer in Europe.
Chemical-free products through solventless technology. Our equipment separated medicine from plants using water.
LED lighting is utilized in the facility, increasing efficiency and reducing our need for low voltage power compared to traditional lighting systems.
Our analytical lab ensures high quality standards, and our plant tissue culture lab contains our genetic library of cannabis cultivars, providing our propagation team with the genetic stock plants needed to produce thousands of cannabis plant clones.
Best Practices
Phare is positioned to be the leading cannabis and cannabinoid manufacturer in the EU, leveraging over 100 years of combined experience operating in the North American and European markets.
- Phare has been producing the highest quality cannabis in the world in North America and Europe, employing the best practices in the industry, yielding the highest benefits and cannabis medicine on the market.
- We meet or exceed all EU GMP and GaCP standards for manufacturing and cultivation.
Genetics
Our Genetics are selected based on specific Pheno-cannabinoid standards and traits allowing Phare to target treatments for specific ailments.
The key to differentiating from other cannabis companies is plant genetics. Our cultivation team has been breeding thousands of cannabis cultivars for over twenty years. As a result, our selection of cannabis is wholly unique.
Our plant genetics are selected based on specific pheno-chemical standards and traits set by our cultivation team. Most of Phare's plant profiles selected for the EU market exhibit high concentrations of cannabinoids, terpenes, and flavonoids.
Medicine for All
Our facility is strategically located in Kalamata, Greece, allowing us to leverage a skilled agricultural workforce to produce medicinal products at a fraction of the cost of other EU manufacturers, ensuring distribution and lower costs for patients.
In Greece, we benefit from an incredibly talented pool of agricultural workers, who maintain a high quality standard of output, while keeping expenses low, due to more affordable compensation rates.
We hold the “High Productivity” license, authorizing us to cultivate cannabis in a high productivity area of Greece, equipped with accessible utilities, commerce, and public works, reducing our risk to product quality and increasing our access to distributors and customers.
Kalamata boasts a large shipping port and an airport, which further reduce the risk of product loss and lowers shipping expenses.
Kalamata boasts an ideal climate for cannabis production, as it offers optimal light, humidity, and the mild seasons necessary to produce high-quality cannabis. No other company is licensed to produce cannabis in Peloponnese.
Scale
Phare Pharmaceuticals has the fortune of being the largest licenced facility in Greece
Our cannabis facility is one of the largest in Europe, with the potential to seize a significant portion of the market. This allows us to maintain a low wholesale price, and to create multiple branded and white-label products, generating product diversity.
Our scale allows us to offer an extremely diverse menu of products to our wholesalers. We have the ability to release several new cannabis cultivars and concentrate products every quarter, creating relevance in the market.
Get in touch today
